Immunological and Clinical Aspects of Multiple Sclerosis: The Proceedings of the XXV Anniversary Symposium of the Belgian Research Group for Multiple SclerosisR.E. Gonsette, P.H. Delmotte Looking back is a luxury for which scientists normally have little time. This XXV Anniversary Symposium, however, gives the opportunity of reminding us that in Belgium, where the risk of developing multiple sclerosis is among the highest in the world, a great man to whom we all pay tribute, I mean Dr Ludo van Bogaert, in 1957, took the initiative in founding the Belgian Research Group for Multiple Sclerosis. It may sound immodest but since that time members of the Belgian Research Group happen to have an honourable record of important contributions to MS research, quite out of proportion to the financial support they received for it. Indeed, when compared to the situation in English speaking countries, funding of MS research has always been neglected in our country in spite of the fact that in 1958, acting on the advice of the Belgian Research Group, the Belgian National MS Society was founded with the specific object of collecting money for research as well as for social care. At that time, the difficulty in raising funds for research was partly due to the fact that solving the problem of MS appeared almost impossible. Scientists could apparently only too slowly improve their ability to prevent and cure the disease. Media were indifferent to MS which was considered to have no news value, and the public remained uninformed. |
Contents
Studies on the intrathecal humoral immunity in multiple | 10 |
Cerebrospinal fluid antibodies detect brain antigens | 16 |
Acid phosphatase activity of cerebrospinal fluid cells | 20 |
Copyright | |
52 other sections not shown
Other editions - View all
Immunological and Clinical Aspects of Multiple Sclerosis: The Proceedings of ... R.E. Gonsette,P.H. Delmotte No preview available - 2012 |
Immunological and Clinical Aspects of Multiple Sclerosis: The Proceedings of ... R.E. Gonsette,P.H. Delmotte No preview available - 2012 |
Common terms and phrases
a-albumin abnormal Acta Neurol acute Ag-SI antibodies antigen assay azathioprine blood blood-brain barrier bout brain central nervous system cerebroside cerebrospinal fluid chronic progressive Clin clinical control group correlation course CSF IgG demonstrated demyelination detected diagnosis disability duration effect evaluation exacerbations experimental allergic encephalomyelitis factors fatty acids Figure ganglioside glycolipids Guillain-Barré syndrome immune complexes immunoglobulin Immunol immunological immunosuppression immunosuppressive treatment increased intrathecal Kurtzke lesions levels lymphocytes measles virus method monoclonal months multiple sclerosis multiple sclerosis patients myelin basic protein neurological diseases neutral proteinase activity ng/ml normal number of patients observed oligoclonal bands onset optic neuritis patients with multiple plasma PMN neutral proteinase Raji cells reaction reactivity relapse rate samples Scand score sensitization sera serum significant spasticity specific spinal stimulation suppressor suppressor cells symptoms Table therapeutic therapy tissue titre tizanidine Tr/Tau ratio trial values